Insulin is a useful structural reference because its mature molecule contains two peptide chains joined in a defined arrangement. A sequence list alone does not capture that arrangement, and a single molecular picture does not capture every stage of receptor engagement. This guide explains how to read those different representations of the same research system.
Count chains and bonds separately
RCSB’s structural account describes human insulin as an A chain of 21 residues and a B chain of 30 residues. Two disulfide bridges connect the chains; a third lies within the A chain.RCSB PDB-101 — Insulin structure and conformation (opens in a new tab)
The total is 51 residues, but writing a single uninterrupted 51-residue sequence would lose the mature molecule’s chain boundaries. A chain identifier is part of a residue address, not decorative notation.
| Quantity | Value | What it counts |
|---|---|---|
| Peptide chains | 2 | Separate mature backbones |
| Residues | 51 | A-chain plus B-chain amino acids |
| Disulfide bonds | 3 | Two links between chains and one within A |
This distinction matters when reading a mutation name. A change at B24 is not a change at residue 24 of the A chain or necessarily at position 24 of the translated precursor. Always retain the numbering reference.
Two mature chains can come from one precursor
Steiner and colleagues’ 1967 study tracked labelled amino acids in human islet-tumour tissue and isolated rat islets. Label appeared in a larger protein before appearing in insulin, and transfer experiments supported a precursor relationship. The authors proposed the name proinsulin.Steiner and colleagues — Insulin biosynthesis: evidence for a precursor (opens in a new tab)
The result addressed biosynthetic order. It supplied evidence that the larger material preceded insulin, rather than merely showing two proteins with similar properties.
For interpreting a structure record, this means that a proinsulin model and a mature insulin model are different molecular stages. Regions present in the precursor should not be assumed to remain in the mature hormone.
Receptor engagement can change the hormone’s conformation
Menting and colleagues’ 2013 work examined insulin bound to truncated insulin-receptor constructs. The structures showed engagement involving the receptor’s alpha-chain carboxyl-terminal segment, with displacement of the insulin B-chain terminal region from its unbound arrangement.Menting and colleagues — Insulin engagement of its primary receptor site (opens in a new tab)
The study combined structural observations with additional interaction experiments. It provided evidence for a conformational change associated with primary-site engagement, rather than assuming that a free hormone docks without changing shape.Menting and colleagues — Insulin engagement of its primary receptor site (opens in a new tab)
That matters when comparing pictures. A difference between a free insulin model and a bound model may represent a relevant molecular state, not an error in one illustration.
However, the crystal constructs were not the complete receptor operating within a living cell. The structural result should not be described as a direct measurement of every later signalling event or metabolic response.
Inspect what the structural experiment includes
Before using an insulin structure to explain a paper, record whether it represents mature human insulin, a modified sequence or a precursor. Then identify the bound partner and any receptor truncation.
Separate residues present in the experimental material from residues resolved in the model. A flexible region can be difficult to resolve; absence from a coordinate image does not by itself prove that it was absent from the sample.
Finally, distinguish the observation from the proposed mechanism. A contact supports an interaction model; a functional perturbation can test its contribution; a cellular response tests another level of the system.
This makes insulin a clear reference for learning how structure informs biology without treating one static model as a complete explanation. The article does not compare treatment regimens, provide dosing advice or assess product interchangeability.
Sources and further detail
- RCSB PDB-101 — Insulin structure and conformation (opens in a new tab)
Structural chain lengths and intra/interchain disulfide description checked. Clinical-use sections are outside this article’s scope.
- Steiner and colleagues — Insulin biosynthesis: evidence for a precursor (opens in a new tab)
Original 1967 abstract read for labelling order and precursor inference. Laboratory procedures are not reproduced.
- Menting and colleagues — Insulin engagement of its primary receptor site (opens in a new tab)
Original 2013 abstract and indexed structural-result passages read. Truncated receptor constructs, conformational interpretation and unresolved regions distinguished from whole-cell signalling.
Sources checked 19 September 2026. Worked examples are illustrative unless a supplied report is explicitly identified. This article has not undergone independent scientific peer review.